Carmen Bozic Sells 2,280 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $488.46, for a total transaction of $1,113,688.80. Following the sale, the chief marketing officer now owns 25,539 shares of the company’s stock, valued at $12,474,779.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Carmen Bozic also recently made the following trade(s):

• On Wednesday, July 10th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $487.34, for a total transaction of $1,111,135.20.
• On Wednesday, June 26th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60.
• On Wednesday, June 12th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $478.00, for a total transaction of $1,089,840.00.
• On Wednesday, May 29th, Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $445.56, for a total transaction of $1,015,876.80.

Vertex Pharmaceuticals Stock Up 0.2 %

Shares of Vertex Pharmaceuticals stock traded up $0.85 on Thursday, hitting $491.65. The company had a trading volume of 745,007 shares, compared to its average volume of 1,209,155. The firm has a market capitalization of $126.87 billion, a P/E ratio of 31.85, a P/E/G ratio of 2.52 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $340.20 and a twelve month high of $503.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The stock has a 50-day moving average of $472.14 and a 200-day moving average of $436.37.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. During the same quarter in the previous year, the firm posted $2.67 earnings per share. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.19 earnings per share for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Shelter Ins Retirement Plan bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at about $12,937,000. Institute for Wealth Management LLC. raised its position in shares of Vertex Pharmaceuticals by 0.6% in the second quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company’s stock valued at $1,681,000 after purchasing an additional 22 shares during the period. Baillie Gifford & Co. bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at about $78,565,000. RFP Financial Group LLC grew its stake in shares of Vertex Pharmaceuticals by 17.0% in the second quarter. RFP Financial Group LLC now owns 158 shares of the pharmaceutical company’s stock valued at $74,000 after acquiring an additional 23 shares in the last quarter. Finally, First National Bank of Hutchinson grew its stake in shares of Vertex Pharmaceuticals by 2.1% in the second quarter. First National Bank of Hutchinson now owns 2,359 shares of the pharmaceutical company’s stock valued at $1,106,000 after acquiring an additional 48 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on VRTX shares. Royal Bank of Canada cut their price target on shares of Vertex Pharmaceuticals from $424.00 to $421.00 and set a “sector perform” rating on the stock in a report on Tuesday, June 11th. TD Cowen raised their price target on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler raised their target price on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. Guggenheim raised their target price on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $460.30.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.